1-3 of 3
Herbert Struemper
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Population Pharmacokinetics (PopPK) and Exposure-Response (E-R) Analyses for Belantamab Mafodotin Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Enrolled in DREAMM-2 and DREAMM-3

Geraldine Ferron-Brady, Adekemi Taylor, Josh Kaullen, Kishore Polireddy, Astrid McKeown, Neal Sule, Herbert Struemper
Journal: Blood
Blood (2023) 142 (Supplement 1): 6730.
https://doi.org/10.1182/blood-2023-178026
Published: 2023
Journal Articles

Exposure-Response (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

Geraldine Ferron-Brady, PhD, Chetan Rathi, PhD, Jon Collins, PhD, Herbert Struemper, PhD, Joanna Opalinska, MD, Roxanne C Jewell, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–21.
https://doi.org/10.1182/blood-2020-139698
Published: 2020
Journal Articles

Phase I Trial Evaluating the Safety and Biological Activity of Iboctadekin (rhIL-18) in Combination with Rituximab in Patients with CD20+ B Cell Non-Hodgkin's Lymphoma,

Michael J. Robertson, MD, John Bauman, Olivia Gardner, Zdenka Jonak, Herbert Struemper, Fiona Germaschewski, Kevin M. Koch, Sharon Murray, Jill Weisenbach, RN, John Toso, MD, MSc
Journal: Blood
Blood (2011) 118 (21): 3697.
https://doi.org/10.1182/blood.V118.21.3697.3697
Published: 2011